Iambic Therapeutics (IAM) News
NASDAQ: IAMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IAM news summary
We found 6 recent headlines mentioning Iambic Therapeutics (IAM): 3 in the past week and 5 in the past 30 days, most often from GlobeNewswire, Nasdaq, Seeking Alpha. IAM is making an outsized move today, down 8.06% at $13.11, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Iambic Presents Preclinical Data for CDK2/4 Inhibitor IAM-C1 and Brain-Penetrant KIF18A Inhibitor IAM217 at 2026 EORTC-NCI-AACR Symposium", was published by GlobeNewswire on Nov 18, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Iambic Therapeutics headlines
- Iambic Presents Preclinical Data for CDK2/4 Inhibitor IAM-C1 and Brain-Penetrant KIF18A Inhibitor IAM217 at 2026 EORTC-NCI-AACR SymposiumIambic announces preclinical data for two wholly owned drug candidates designed using AIGlobeNewswire
- Iambic Therapeutics, Inc. GAAP EPS of -$8.52 misses by $7.75, revenue of $11.4M beats by $3.11MSeeking Alpha
- Iambic Provides Business Updates and Third Quarter 2026 Financial ResultsIambic (Nasdaq: IAM) Provides Business Updates and Third Quarter 2026 Financial ResultsGlobeNewswire
- Iambic Shares Rise Ahead Of AI Drug Discovery Panel At Jefferies Healthcare Conference(RTTNews) - Iambic Therapeutics (IAM) on Monday, announced that its Co-Founder and Chief Executive Officer, Tom Miller, will participate in a panel discussion focused on artificial intelligence (AI)…NasdaqIAM, BF.A
- Iambic to participate in Jefferies Global Healthcare ConferenceCo-Founder and CEO Tom Miller joins AI drug discovery panel on November 18, 2026 Co-Founder and CEO Tom Miller joins AI drug discovery panel on November 18, 2026GlobeNewswire
- Tuesday 10/20 Insider Buying Report: IAM, FISAs the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. On…NasdaqIAM, FIS